ABBOTT AXSYM ANTIBODY TO HCV (ANTI-HCV)
FDA premarket approval P970027/S007 · decided 2009-07-08
Approval details
- PMA number
- P970027
- Supplement
- S007
- Supplement type
- Real-Time Process
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- ABBOTT AXSYM ANTIBODY TO HCV (ANTI-HCV)
- Generic name
- Assay, enzyme linked immunosorbent, hepatitis c virus
- Applicant
- Abbott Laboratories
- Date received
- 2008-11-13
- Decision date
- 2009-07-08
- Days to decision
- 237 days
- Decision code
- APPR
- Product code
- MZO
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- Abbott Park, IL
- Statement
- APPROVAL FOR A CHANGE IN THE ANTIMICROBIAL FORMULATION TO THE AXSYM ANTI-HCV REAGENT SDB2 (SPECIMEN DILUENT). IN ADDITION, DUE TO THE REFORMULATION OF THE SDB2, THE INSTRUCTION TO USE STERILE WATER FOR TUBING DECONTAMINATION IS NO LONGER A REQUIRED PROCEDURE AND CAN BE REMOVED FROM THE PACKAGE INSERT LABELING.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| Anti-HCV Next (K252424) | Abbott Laboratories | 2026-04-28 |
| ARCHITECT iGentamicin (K243500) | Abbott Laboratories | 2025-07-09 |
| Alinity i Rubella IgG (K243168) | Abbott Laboratories | 2025-06-20 |
| Alinity h-series System (K243283) | Abbott Laboratories | 2025-02-20 |
| Alinity i Toxo IgM (K233932) | Abbott Laboratories | 2024-08-30 |
| TBI (K232669) | Abbott Laboratories | 2023-09-29 |
| HAVAb IgG II (K222850) | Abbott Laboratories | 2023-08-10 |
| Alinity h-series System (K220031) | Abbott Laboratories | 2023-08-04 |